The overall purpose of this Program Project application is to understand the molecular and neuronal mechanisms that lead to individual differences in emotional responsiveness, and to apply this understanding to uncovering the biological basis of vulnerability to major depressive disorder (MDD). Like many common disorders, MDD is a heterogeneous illness with a complex genetic nature, involving interacting genes An essential element in the vulnerability to the illness is how one reacts and copes with stress and anxiety provoking situations. This is determined at the level of the brain, and involves critical neuronal circuits that control emotional responsiveness. Thus it is important to characterize the biological basis of differences in emotional reactivity in animal models, and use this knowledge in our efforts to understand vulnerability to mood disorders in humans. To this end, we plan to focus on a particular set of known candidate systems-the stress system and the serotonergic and noradrenergic systems that closely interact with it. But, we also plan to search for novel candidate genes using microarray technology and to begin to explore their relationship to differences in emotional reactivity. We plan to study the known and the novel candidate molecules under both basal to define the neuronal phenotypes (patterns of gene expression in the brain) that accompany the behavioral differences in emotional responsiveness. Project 1 (Subproject 0013) is concerned with stress-serotonin interactions, as well as the discovery of novel candidates that are differentially expressed in animals with different emotional responsiveness. Project 2 (Subproject 0010) focuses on stress- noradrenaregic interactions in rats. In addition, it involves the study of these interactions in human postmortem brain tissue from depressed individuals and matched controls. Project 3 (Subproject 0011) uses a developmental approach to uncover the unfolding of the behavioral differences in emotional responsiveness and their neuronal correlates in the rat. Project 4 (Subproject 0012) uses mouse genetic approaches to over- or under-express the corticosteroid receptors in a tissue specific and inducible manner and study the effects on emotionality Project 5 (Subproject 0013) will involve the study of depressed individual using a combination of neuroendocrine and neuroimaging approaches to investigate individual differences in the interaction between the stress and serotonin system and its relevance to treatment response. The components of this project are highly complementary and synergistic. It is hoped that their completion will shed light on the molecular, neurobiological and environmental factors that lead to increased vulnerability to depression and affect the individual's response to the treatment of this illness.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program Projects (P01)
Project #
5P01MH042251-20
Application #
7005674
Study Section
Special Emphasis Panel (ZMH1-BRB-P (02))
Program Officer
Winsky, Lois M
Project Start
1992-03-01
Project End
2007-11-30
Budget Start
2005-12-01
Budget End
2007-11-30
Support Year
20
Fiscal Year
2006
Total Cost
$1,362,391
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Psychiatry
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hillhouse, Todd M; Porter, Joseph H (2015) A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 23:1-21
Meyers, K K; Crane, N A; O'Day, R et al. (2015) Smoking history, and not depression, is related to deficits in detection of happy and sad faces. Addict Behav 41:210-7
Lohoff, F W; Hodge, R; Narasimhan, S et al. (2014) Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Mol Psychiatry 19:129-39
Votruba, Kristen L; Langenecker, Scott A (2013) Factor structure, construct validity, and age- and education-based normative data for the Parametric Go/No-Go Test. J Clin Exp Neuropsychol 35:132-46
Tomita, Hiroaki; Ziegler, Mary E; Kim, Helen B et al. (2013) G protein-linked signaling pathways in bipolar and major depressive disorders. Front Genet 4:297
Turner, Cortney A; Watson, Stanley J; Akil, Huda (2012) The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 76:160-74
Vederman, Aaron C; Weisenbach, Sara L; Rapport, Lisa J et al. (2012) Modality-specific alterations in the perception of emotional stimuli in Bipolar Disorder compared to Healthy Controls and Major Depressive Disorder. Cortex 48:1027-34
Turner, Cortney A; Clinton, Sarah M; Thompson, Robert C et al. (2011) Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc Natl Acad Sci U S A 108:8021-5
Mickey, Brian J; Zhou, Zhifeng; Heitzeg, Mary M et al. (2011) Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 68:158-66

Showing the most recent 10 out of 75 publications